Free Trial
→ Watch This Robotics Demo Before March 17th (From Brownstone Research) (Ad)

PTC Therapeutics Q2 2023 Earnings Report

PTC Therapeutics logo
$50.69 +0.31 (+0.62%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

PTC Therapeutics EPS Results

Actual EPS
-$2.66
Consensus EPS
-$1.58
Beat/Miss
Missed by -$1.08
One Year Ago EPS
-$2.13

PTC Therapeutics Revenue Results

Actual Revenue
$213.80 million
Expected Revenue
$206.99 million
Beat/Miss
Beat by +$6.81 million
YoY Revenue Growth
+29.20%

PTC Therapeutics Announcement Details

Quarter
Q2 2023
Date
8/3/2023
Time
After Market Closes

PTCT Upcoming Earnings

PTC Therapeutics will be holding an earnings conference call on Thursday, February 27 at 4:30 PM Eastern. Interested parties can register for or listen to the call.

Conference Call Resources

Conference Call Audio

Powered by Quartr

PTC Therapeutics Earnings Headlines

PTC Therapeutics to Participate in Upcoming Investor Conferences
February 20 at 8:00 AM | prnewswire.com
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $58.85 Consensus Target Price from Brokerages
February 20 at 1:31 AM | americanbankingnews.com
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
February 22, 2025 | Investors Alley (Ad)
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia
February 19 at 7:00 AM | prnewswire.com
Royal Bank of Canada Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price
February 19 at 3:47 AM | americanbankingnews.com
PTC Therapeutics (NASDAQ:PTCT) Stock Rating Lowered by StockNews.com
February 19 at 1:43 AM | americanbankingnews.com
See More PTC Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PTC Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PTC Therapeutics and other key companies, straight to your email.

About PTC Therapeutics

PTC Therapeutics (NASDAQ:PTCT), a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

View PTC Therapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles